文献速递肾小球疾病慢性肾脏病

利妥昔单抗治疗儿童激素抵抗型肾病综合征的肾脏生存

Kidney Survival in Children With Steroid-Resistant Nephrotic Syndrome Treated by Rituximab.
PubMed 文献 · Kidney Int Rep · 2026-06-03

该国际回顾性队列研究纳入17国23中心的151例CNI无应答且无遗传变异的SRNS患儿,加用利妥昔单抗后3、5、7年肾脏生存率分别为82.7%、75.8%、72.3%。基线CKD分期、低白蛋白、FSGS及6个月未缓解与更差肾脏生存相关。

要点

  • 加用利妥昔单抗后3-7年肾脏生存约70%-80%。
  • 基线CKD分期越高、血清白蛋白越低、病理为FSGS者肾脏生存更差。
  • 6个月未达完全或部分缓解者5年肾脏生存仅61.2%。

核心结论

  • SRNS患儿在CNI无应答后加用利妥昔单抗,3至7年肾脏生存率为70%至80%。
  • 未缓解、既存CKD、低白蛋白及FSGS预示更差的肾脏生存。

研究设计与样本

  • 国际回顾性队列研究,覆盖17国23中心,纳入151例CNI无应答且无遗传变异的SRNS患儿。

主要发现

  • 151例患儿中53%为男性,起病中位年龄6.8岁,原发性与继发性SRNS分别占54%与46%,FSGS占62%。
  • 总体肾脏生存率在利妥昔单抗后3、5、7年分别为82.7%、75.8%、72.3%。
  • 基线CKD分期与5年肾脏生存相关(log-rank P < 0.001):CKD1期91.7%,CKD2期70.4%,CKD3期35.5%。
  • 6个月未缓解者5年肾脏生存61.2%,而完全或部分缓解者为100%(log-rank P = 0.01;HRadj 14.1,95%CI 2.2-93.5,P = 0.01)。

关键数值与推荐

  • 基线CKD2期与更差肾脏生存独立相关(HRadj 2.7,95%CI 1.5-4.9,P < 0.001)。
  • 基线血清白蛋白每降低单位与更差肾脏生存相关(log-rank P = 0.01;HRadj 0.88,95%CI 0.81-0.95,P < 0.001)。
  • FSGS与更差肾脏生存相关(log-rank P = 0.03;HRadj 3.4,95%CI 1.1-10.0,P < 0.001)。
  • 既往钙调磷酸酶抑制剂使用时长及SRNS类型不是显著预测因素。

临床怎么用

  • 对CNI无应答的SRNS患儿,加用利妥昔单抗前应评估基线CKD分期、血清白蛋白及病理类型以分层预后。
  • 利妥昔单抗后6个月缓解状态与肾脏生存密切相关,未缓解者需密切监测肾功能。

局限性

  • 回顾性研究设计可能引入选择偏倚和信息偏倚。
  • 排除遗传变异患者,结论不适用于遗传性SRNS。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Kidney outcomes in children with steroid-resistant nephrotic syndrome (SRNS) following rituximab remain unclear. METHODS: We conducted an international retrospective cohort study across 23 centers in 17 countries, including children with SRNS who did not respond to calcineurin inhibitors (CNIs) and subsequently, received rituximab. Patients with genetic variants were excluded. The primary outcome was kidney survival. RESULTS: We analyzed data on 151 children (53% males; median age at onset: 6.8 years; primary vs. secondary SRNS: 54% vs. 46%; focal segmental glomerulosclerosis [FSGS]: 62%). All subjects received CNIs before rituximab (0-3 months: 21%; 3-6 months: 26%; 6-12 months: 26%; > 12 months: 26%). Upon rituximab, 73 subjects (48%) had normal kidney function, 47 (31%) had chronic kidney disease (CKD)2, and 31 (21%) had CKD3. Twenty-eight (19%) developed kidney failure. Overall kidney survival was 82.7%, 75.8%, and 72.3% at 3, 5, and 7 years post-rituximab. Baseline CKD staging before rituximab was associated with kidney survival at 5 years (log-rank P < 0.001); CKD stage 1, 91.7%; CKD stage 2, 70.4%; and CKD stage 3, 35.5%). The predictive factors for inferior kidney survival were CKD2 (adjusted hazard ratio [HRadj]: 2.7, 95% confidence interval [CI]: 1.5-4.9, P < 0.001), lower baseline serum albumin (log-rank P = 0.01; HRadj: 0.88, 95% CI: 0.81-0.95; P < 0.001) and FSGS (log-rank P = 0.03; HRadj: 3.4, 95% CI: 1.1-10.0; P < 0.001). Nonremission at 6 months was associated with inferior kidney survival (61.2% at 5 years), compared with complete remission (CR) or partial remission (PR) (100% at 5 years) (log-rank P = 0.01; HRadj: 14.1, 95% CI: 2.2-93.5, P = 0.01). Duration of prior calcineurin inhibition and SRNS type were not significant predictors. CONCLUSION: Kidney survival of SRNS following add-on rituximab is 70% to 80% over 3 to 7 years. Nonresponse, preexisting CKD, lower albumin, and FSGS predict inferior kidney survivals.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Chan EY, Ho IY, Au CT, et al. Kidney Survival in Children With Steroid-Resistant Nephrotic Syndrome Treated by Rituximab. Kidney Int Rep. 2026. PMID: 42437162. doi:10.1016/j.ekir.2026.106638

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。